全球尿路上皮癌治疗市场 – 行业趋势及 2030 年预测

尿路上皮癌治疗市场分析及规模

根据世界癌症研究基金会国际记录，膀胱癌是全球第九大常见癌症，2012年确诊的新病例约43万例。据观察，确诊时约70%的病例为非肌层浸润性疾病，20%为肌层浸润期，10%为晚期。约59%的膀胱癌病例发生在北美和欧洲等高度发达地区。尿路上皮癌对经济和人类造成的损失意味着极不成比例的健康负担。

Data Bridge Market Research 分析了 2023-2030 年预测期内全球尿路上皮癌治疗市场的增长率。在上述预测期内，全球尿路上皮癌治疗市场的预期复合年增长率趋于 20% 左右。2022 年市场价值为 8.1 亿美元，到 2030 年将增长至 34.8 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

尿路上皮癌治疗市场范围和细分

Market Definition

Urothelial carcinoma is a type of disorder that begins when urothelial cells in the bladder lining changes and grow abnormally leading into the formation of a mass called tumor. It is the most common type of bladder cancer. A person suffering from bladder cancer also have a fair chance of having tumors in ureter, urethra, renal pelvis. The complication occurs when bladder cancers may spread to deeper bladder layers and becomes difficult to control. The typical symptoms of urothelial carcinoma include blood in the urine, pain, irritation in bladder, urination habits changes, edema, night sweats, weight loss and fever.

Global Urothelial Carcinoma Treatment Market Dynamics

Drivers

• Increase in Bladder Cancer

The growing prevalence of bladder cancer across the world supports the market expansion during the forest period. For instance, the Global Cancer Observatory Statistics 2020 reported that bladder cancer and prostate cancer are the leading cancer occurrences around the world. It has also been reported that in 2020, the projected number of new cases of bladder cancer was around 573,278, and that of prostate cancer was 1,414,259 cases among both sexes in the year 2020. Such a high occurrence of cancer globally is boosting the market growth.

• Rising Demand for Chemotherapy

Chemotherapy is considered as the first-line treatment for urothelial cancer. According to the study published in January 2020 titled "Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis", gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) have been considered the first-line treatments for advanced or metastatic urothelial carcinoma (AMUC). Thus, this boosts the market growth.

Opportunities

• Increased Drug Approvals

There are recent approvals from major market players that create much opportunities for the market growth. For instance, the urothelial cancer drugs market is likely to be benefitted from better therapies that are being approved by leading drug regulatory organizations. For instance, in April 2020, China National Medical Products Administration (NMPA) approved tislelizumab developed by BeiGene for the treatment of advanced or metastatic urothelial carcinoma. Numerous novel treatments are predicted to see approvals, further supporting the growth of the market.

• Rising Healthcare Stategies

Numerous strategies has been adopted by the major market players which are boosting the market growth. For instance, in June 2020, Pfizer received the U.S. FDA approval for BAVENCIO. It has been approved as the first-line maintenance treatment among patients who are suffering from advanced or metastatic urothelial carcinoma. Additionally, in April 2020, UroGen Pharma received the U.S. FDA approval for mitomycin gel that has been indicated for the treatment of low-grade upper tract urothelial cancer . This creates more opportunities in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of skilled healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could restrict the growth of the global urothelial carcinoma treatment market during a forecast period.

• High Cost

The huge expenditure of the treatment methods hamper the market growth. The high R&D cost associated with the manufacturing of urothelial cancer drugs, along with increased penetration of generic drugs, is likely to impede the market growth.

This global urothelial carcinoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global urothelial carcinoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In April 2022, Pfizer made an equity investment worth USD 25 million in Zentalis Pharmaceuticals, Inc. The aim behind this investment is to help Pfizer to leverage its development capabilities worldwide.
• In June 2022, Roche introduced a human papillomavirus (HPV) self-sampling solution which enables patients to conduct HPV screening in the presence of a healthcare professional. This is anticipated to expand the company’s cancer screening solution line-up.

Global Urothelial Carcinoma Treatment Market Scope

The global urothelial carcinoma treatment market is segmented on the basis of treatment, type, diagnostic test, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Papillary
• Flat Carcinoma

Treatment

• Chemotherapy
• Radiotherapy
• Immunotherapy  

Diagnostic Test

• Urine Cytology
• Biopsy
• Computed tomography scanning
• Ultrasound Imaging
• Cystoscopy
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Urothelial Carcinoma Treatment Market Regional Analysis/Insights

The global urothelial carcinoma treatment market is analyzed and market size insights and trends are provided by treatment, type, diagnostic test, distribution channel and end-user as referenced above.

The major countries covered in the global urothelial carcinoma treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key manufacturers of the product, increasing research and development activities, healthcare expenditure, and skilled professionals in the region. 

Asia-Pacific dominates the market due to increased new research and developments on urothelial carcinoma treatment market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Urothelial Carcinoma Treatment Market Share Analysis

全球尿路上皮癌治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球尿路上皮癌治疗市场的关注有关。

全球尿路上皮癌治疗市场的主要参与者包括：

• 强生私人有限公司（美国）
• 雅培（美国）
• AbbVie Inc.（美国）
• Bausch Health Companies Inc.（加拿大）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• Hikma Pharmaceuticals PLC（英国）
• Amneal Pharmaceuticals LLC.（美国）
• 辉瑞公司 (美国)
• Mylan NV（美国）
• 百时美施贵宝公司 (美国)
• 拜耳公司（德国）
• Dendreon Pharmaceuticals LLC（美国）
• 卫材株式会社（日本）
• 基因泰克公司（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• UroGen Pharma, Inc.（美国）
• Konninklije Philips NV（荷兰）
• 奥林巴斯株式会社（日本）
• 太平洋边缘（新西兰）
• AroCell AB（瑞典）
• 安捷伦科技公司（美国）

研究方法：全球尿路上皮癌治疗市场

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息，请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（Factbook）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

SKU-55769